Indivior logo

INDV - Indivior Share Price

51.84p -0.1  -0.2%

Last Trade - 18/10/19

Sector
Healthcare
Size
Mid Cap
Market Cap £378.8m
Enterprise Value £-155.5m
Revenue £720.8m
Position in Universe 623rd / 1855
Bullish
Bearish
Unlock INDV Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

INDV Revenue Unlock INDV Revenue

Net Income

INDV Net Income Unlock INDV Revenue

Normalised EPS

INDV Normalised EPS Unlock INDV Revenue

PE Ratio Range

INDV PE Ratio Range Unlock INDV Revenue

Dividend Yield Range

INDV Dividend Yield Range Unlock INDV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2019
31st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
INDV EPS Forecasts Unlock INDV Revenue
Profile Summary

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.

Directors
Last Annual December 31st, 2018
Last Interim June 30th, 2019
Incorporated September 26, 2014
Public Since December 23, 2014
No. of Shareholders: n/a
No. of Employees: 1,024
Sector Healthcare
Industry Pharmaceuticals
Index FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSEurofirst 300 Ex Eurozone, FTSE Smallcap , FTSE Smallcap Ex Its , ,
Exchange London Stock Exchange (Full)
Shares in Issue 730,737,398
Free Float (0.0%)
Eligible for
ISAs
SIPPs
Address 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom
Web http://indivior.com/
Phone +44 1753 217800
Contact ()
Auditors PricewaterhouseCoopers LLP
INDV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for INDV
Upcoming Events for INDV
Thursday 31st October, 2019
Q3 2019 Indivior PLC Earnings Release
Thursday 31st October, 2019
Q3 2019 Indivior PLC Earnings Call
Tuesday 31st December, 2019
Indivior PLC Capital Markets Day
Wednesday 12th February, 2020 Estimate
Full Year 2019 Indivior PLC Earnings Release
Similar to INDV
© Stockopedia 2019, Thomson Reuters, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.